

RESEARCH ARTICLE

STEM CELLS AND REGENERATION

The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation *in vivo* and *in vitro*

Fahad R. Ali^{1,2,*}, Kevin Cheng^{1,*}, Peter Kirwan³, Su Metcalfe², Frederick J. Livesey³, Roger A. Barker² and Anna Philpott^{1,‡}

ABSTRACT

Generation of neurons from patient fibroblasts using a combination of developmentally defined transcription factors has great potential in disease modelling, as well as ultimately for use in regeneration and repair. However, generation of physiologically mature neurons *in vitro* remains problematic. Here we demonstrate the cell-cycle-dependent phosphorylation of a key reprogramming transcription factor, Ascl1, on multiple serine-proline sites. This multisite phosphorylation is a crucial regulator of the ability of Ascl1 to drive neuronal differentiation and maturation *in vivo* in the developing embryo; a phosphomutant form of Ascl1 shows substantially enhanced neuronal induction activity in *Xenopus* embryos. Mechanistically, we see that this un(der) phosphorylated Ascl1 is resistant to inhibition by both cyclin-dependent kinase activity and Notch signalling, both of which normally limit its neurogenic potential. Ascl1 is a central component of reprogramming transcription factor cocktails to generate neurons from human fibroblasts; the use of phosphomutant Ascl1 in place of the wild-type protein significantly promotes neuronal maturity after human fibroblast reprogramming *in vitro*. These results demonstrate that cell-cycle-dependent post-translational modification of proneural proteins directly regulates neuronal differentiation *in vivo* during development, and that this regulatory mechanism can be harnessed to promote maturation of neurons obtained by transdifferentiation of human cells *in vitro*.

KEY WORDS: Ascl1, Neurogenesis, Phosphorylation, Transdifferentiation

INTRODUCTION

Direct transdifferentiation of human fibroblasts into neurons using defined combinations of transcription factors has recently emerged as a powerful new approach for both disease modelling and repair (Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Pfisterer et al., 2011; Yang et al., 2011). However, this is generally an inefficient process and neurons generated typically display phenotypic immaturity. Transdifferentiation using transcription factors has been further enhanced by adding small molecule inhibitors of growth factor pathways (Ladewig et al., 2012). However, the mechanistic basis of the links between the cellular signalling environment and the ability of defined factors to drive

neuronal differentiation is poorly characterized in both normal development and under transdifferentiation conditions.

During development, the proneural transcription factor Ascl1 (also known as Mash1) is a crucial regulator of multiple aspects of neurogenesis, including progenitor cell maintenance, neuronal differentiation and neurite outgrowth in the central and peripheral nervous systems (Bertrand et al., 2002; Castro and Guillemot, 2011). Moreover, *Ascl1* overexpression alone converts ectodermal cells to ectopic neurons in *Xenopus* embryos (Talikka et al., 2002). *Ascl1* is also a central and common component of a variety of methods developed for reprogramming of mouse and human fibroblasts into neurons *in vitro* (Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Pfisterer et al., 2011). For instance, introduction of the ‘BAM’ factors *Ascl1*, *Brn2* (*Pou3f2* – Mouse Genome Informatics) and *Myt1l*, together with *NeuroD*, drives transdifferentiation of human fibroblasts to functional neurons (Yang et al., 2011). However, to enhance the efficacy of this approach, we must fully characterize mechanisms that regulate the activity of factors used for reprogramming. Here, we demonstrate that post-translational modification of Ascl1 by multisite phosphorylation regulates its ability to drive neuronal differentiation and transdifferentiation *in vivo* and *in vitro*.

RESULTS**Ascl1 is regulated by multisite phosphorylation**

Ascl1 is a core component of a variety of transcription factor protocols that have been used to drive transdifferentiation of mammalian fibroblasts directly into neurons (Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Pfisterer et al., 2011; Yang et al., 2011; Torper et al., 2013), but the post-translational control of this protein is largely unknown. Phosphorylation of a number of conserved serine-proline (SP) sites regulates the activity of Ngn2 (Neurog2 – Mouse Genome Informatics) and Olig2 basic helix-loop-helix (bHLH) proneural proteins (Ma et al., 2008; Ali et al., 2011; Gaber and Novitsch, 2011). Ascl1 also contains multiple SP sites (supplementary material Fig. S1) that we hypothesized could be functionally modified through phosphorylation by proline-directed kinases. We see that mouse Ascl1 is subject to multisite phosphorylation in the complex and biologically relevant environment of interphase *Xenopus* egg extracts, resulting in slowed migration on SDS-PAGE that is reversed by phosphatase treatment (Fig. 1A, arrows). Moreover, incubation in mitotic extract leads to a greater reduction in mobility, indicating more phosphorylation in an environment with more Cdk kinase activity (Fig. 1A). Multisite phosphorylation occurs on serines of SP pairs; mutation of all six SP sites in Ascl1 to generate S-A Ascl1 prevented interphase extract-mediated modification of Ascl1 protein, and substantially reduced modification in mitotic extract, indicating that phosphorylation occurs on serines in SP pairs. Further mutational analysis where SP sites are either individually or additively mutated (supplementary material Fig. S1) revealed that multiple SP sites at both the N- and C-terminal either side of the bHLH domain are

¹University of Cambridge, Department of Oncology, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 0XZ, UK. ²John van Geest Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK. ³Gurdon Institute, Department of Biochemistry and Cambridge Stem Cell Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK. *These authors contributed equally to this work

[‡]Author for correspondence (ap113@cam.ac.uk)

Received 22 November 2013; Accepted 6 April 2014




Fig. 1. Ascl1 function is inhibited by SP-directed phosphorylation.

(A) Wild-type and S-A Ascl1 translated *in vitro* in the presence of 35S-methionine and incubated in buffer (XB), *Xenopus* interphase or mitotic egg extracts with or without phosphatase, separated by SDS-PAGE. (B) *Xenopus* embryos injected unilaterally with 100 pg GFP, wild-type Ascl1 or S-A Ascl1, detecting β -III tubulin at stage 19 by *in situ* hybridisation. (C) The percentage of embryos with no difference (0), moderate increase (1) or substantial increase (2) of β -III tubulin expression comparing injected and uninjected sides ($n \geq 57$); *** $P \leq 0.005$. (D) qPCR analysis of Delta, Myt1 and β -III tubulin expression in stage 19 *Xenopus* embryos overexpressing 50 pg Ascl1 or S-A Ascl1 (mean \pm s.e.m.; * $P \leq 0.05$). I, interphase; M, mitotic; WT, wild type.

phosphorylated (supplementary material Fig. S2); mutants with either N-terminal or C-terminal sites intact both show reduced mobility compared with wild-type protein in I and M extracts, although mutations of all SP sites to alanine-proline is required to restore SDS-PAGE mobility of extract-incubated to that of uninjected protein (Fig. 1A; supplementary material Figs S1 and S2).

Serine-proline or threonine-proline is minimally required for Cdk-dependent phosphorylation (Errico, 2010), and we see that Ascl1 undergoes cell cycle-dependent phosphorylation in *Xenopus* egg extracts on these sites (Fig. 1; supplementary material Fig. S2); a mutant in which SP sites have been mutated to alanine-proline shows a dramatic reduction in phosphorylation.

To determine whether Ascl1 can indeed act as a target for Cdks, we incubated Ascl1 protein with active recombinant cyclin/Cdk proteins. When wild-type Ascl1 was incubated with CyclinA/Cdk2, its migration on SDS-PAGE was significantly retarded, and a smear of slower-migrating Ascl1 protein indicates phosphorylation on more than one site (supplementary material Fig. S3). S-A Ascl1 in this assay shows markedly reduced retardation compared with wild-type Ascl1, demonstrating that phosphorylation of Ascl1 occurs on SP sites. It is interesting to note that *in vitro* when incubated with purified kinases, some phosphorylation of S-A Ascl1 still occurs even in the absence of serine-proline and threonine-proline sites, although the physiological relevance of this observation is not clear; *in vitro* kinase assays can show target promiscuity not seen in a more physiological setting. Alternatively, it is possible that Cyclin/Cdks can phosphorylate and activate a kinase in the reticulocyte lysate used for *in vitro* translation that can go on to phosphorylate Ascl1 on non-SP sites.

We did not observe significant SDS-PAGE retardation of Ascl1 as a result of incubation with CyclinD/Cdk4 or CyclinB/Cdk1 (supplementary material Fig. S3). This could indicate an inability of

these Cdks to target Ascl1 in this assay, but could still be compatible with phosphorylation on sites that does not result in a shift on SDS-PAGE, a phenomenon that likely to be amino acid context dependent. To confirm that Cdk2 is able to phosphorylate Ascl1 in *Xenopus* cytoplasm, we added recombinant Cdk inhibitor p27Xic1 (Vernon et al., 2003) to interphase egg extract and noted a marked increase in mobility of Ascl1 migration commensurate with inhibition of phosphorylation (supplementary material Fig. S4). As Cdk2 complexes with CyclinE and not CyclinA at this embryonic stage, and D-type cyclins are not expressed prominently in eggs (Richard-Parpaillon et al., 2004; Philpott and Yew, 2008), this indicates that Ascl1 can also be phosphorylated by CyclinE/Cdk2 (supplementary material Fig. S4).

To assess how SP site phosphorylation affects the ability of Ascl1 to drive ectopic neurogenesis *in vivo*, we overexpressed wild-type Ascl1 and phosphomutant Ascl1 (S-A Ascl1) in *Xenopus* embryos by mRNA microinjection into one cell of a two-cell embryo (Fig. 1B,C; supplementary material Fig. S1). Mutation of SP sites substantially enhanced the ability of S-A Ascl1 to induce ectopic neurogenesis compared with wild type. One possibility is that enhanced activity results from greater protein stability of S-A Ascl1. When protein levels were compared in *Xenopus* embryos, S-A Ascl1 was expressed at a modestly higher level than the wild-type protein (supplementary material Fig. S5A).

We then investigated whether increased S-A Ascl1 activity could be explained by enhanced activation of downstream targets that promote differentiation by the phosphomutant protein. To this end, we compared the effect of wild-type and S-A Ascl1 overexpression on activation of different direct downstream targets with functions in progenitor maintenance or differentiation. Quantitative PCR analysis of injected *Xenopus* embryos showed that S-A Ascl1 overexpression resulted in at least a sevenfold enhancement of

expression of *Myt1* and *Tubb* (β -III tubulin), both markers of neuronal differentiation, compared with induction by wild-type *Ascl1* (Fig. 1D). By contrast, expression of Delta, the Notch ligand involved in non-cell-autonomous progenitor maintenance pathways, is only upregulated twofold by S-A *Ascl1* compared with wild type (Fig. 1D). This indicates that preventing phosphorylation of *Ascl1* on SP sites may preferentially potentiate neuronal differentiation over progenitor maintenance.

Mutation of some SP sites, particularly the two sites in the N-terminus of *Ascl1*, led to a greater shift in SDS-PAGE mobility than mutation of other sites (supplementary material Figs S1 and S2), although it is not clear if this is because of differences in extent of phosphorylation or due to differences in the effect of phosphorylation of different sites on electrophoretic mobility. To see whether phosphorylation on both the N- and C-terminals contributes to the regulation of *Ascl1* transcriptional activity, we overexpressed mutants of N- and C-terminal SP site *Ascl1* mutants (supplementary material Fig. S1) and compared their activity to both wild type and S-A *Ascl1* in *Xenopus* embryos (supplementary material Fig. S6). Neither mutation of the N-terminal or C-terminal SP sites alone was sufficient to significantly enhance neural β tubulin expression, although an approximately 15-fold enhancement was seen when both N- and C-terminal sites were mutated together. This demonstrates that specific sites whose loss of SP phosphorylation may not result in a significant change in migration on SDS-PAGE, nevertheless still contribute substantially to regulation of *Ascl1* activity. We also compared relative activation of Delta and *Myt1* by N- and C-terminal mutants. We saw that mutation of both the N- and C-terminal sites is needed for maximal activation of expression of these targets, but that *Myt1* expression was much more sensitive to the phospho-status of *Ascl1* than Delta expression (supplementary material Fig. S6).

Shortening the cell cycle by upregulation of cyclin-dependent kinase activity promotes progenitor maintenance (Richard-Parpaillon et al., 2004; Hindley et al., 2012). We saw that overexpression of CyclinA2/Cdk2 inhibited endogenous primary neurogenesis in *Xenopus* embryos. Both endogenous neurogenesis and ectopic neurogenesis driven by ectopic wild-type *Ascl1* were inhibited by increased Cdk activity, whereas S-A *Ascl1* was resistant to this inhibition (Fig. 2A,B). Thus, mutation of SP sites on *Ascl1* renders the protein insensitive to Cdk-dependent cues that would otherwise limit neuronal differentiation *in vivo*. Conversely, cell cycle lengthening promotes neuronal differentiation (Lange and Calegari, 2010). We next investigated whether S-A *Ascl1* may also potentiate neuronal differentiation by enhancing cell cycle lengthening/exit compared to

wild-type *Ascl1* by monitoring phospho-histone H3 (pH3) expression after *Ascl1* overexpression. Both wild-type and S-A *Ascl1* inhibited pH3 expression by similar amounts, indicating that phosphomutant *Ascl1* does not enhance neurogenesis by potentiating cell cycle lengthening (Fig. 3A).

There are other mechanisms by which cell cycle regulators can influence proneural protein function beyond regulation by Cdk-dependent phosphorylation (Hindley and Philpott, 2012). For instance, we have previously shown that the *Xenopus* Cdk inhibitor, p27Xic1, is absolutely required for Ngn2-dependent differentiation of primary neurons in *Xenopus* beyond its ability to lengthen the cell cycle (Vernon et al., 2003). Cell cycle lengthening/exit upon *Ascl1* expression, as evidenced by reduction in pH3 expression, is likely to be accompanied by upregulation of Cdkis (Farah et al., 2000). However, a requirement for Cdkis in *Ascl1*-mediated neurogenesis has not been investigated, nor has whether any such requirement is dependent on the ability of *Ascl1* to be phosphorylated on Cdk sites. To investigate whether p27Xic1 is required for *Ascl1*-induced neurogenesis, *Xenopus* embryos were injected in one cell at the two-cell stage with *Ascl1* or S-A *Ascl1*, with either a control antisense morpholino (Con Mo) or a morpholino directed against *Xic1* (*Xic1* Mo), which has previously been shown to efficiently block *Xic1* protein expression (Vernon et al., 2003). The control morpholino had no discernible impact on neurogenesis, whereas *Xic1* Mo injection inhibited both endogenous primary neurogenesis and ectopic neurogenesis induced by *Ascl1* expression (Fig. 3B,C), demonstrating that wild-type *Ascl1* requires Cdk inhibitor activity for the efficient induction of differentiated neurons. By contrast, S-A *Ascl1* retained its ability to induce neuronal differentiation even in the absence of p27Xic1 protein. We then investigated whether enhancing p27Xic1 levels can promote *Ascl1*-driven neurogenesis as it can for Ngn2 (Vernon et al., 2003). Co-injection of low levels of p27Xic1 that are sufficient to substantially slow the cell cycle (Vernon et al., 2003) resulted in enhancement of *Ascl1*-mediated ectopic neurogenesis. However, significant synergy between p27Xic1 and S-A *Ascl1* was not observed (Fig. 3B,C).

Proneural proteins including *Ascl1* transcriptionally upregulate the Notch ligand Delta (Casarosa et al., 1999) that inhibits neuronal differentiation in adjacent cells via Notch signalling in a process known as lateral inhibition (Chitnis et al., 1995). In *Xenopus*, overexpression of the constitutively active Notch intracellular domain (NICD) can inhibit both endogenous neurogenesis and proneural protein-driven ectopic neurogenesis. Post-translational inhibition of proneural proteins by Notch is relieved by expression




Fig. 2. Phosphomutant *Ascl1* confers resistance to cell cycle inhibition of neurogenesis. (A) *Xenopus* embryos were injected unilaterally in one of two cells, injected side to right, with either 100 pg of GFP or wild-type/S-A *Ascl1* mRNA, and 500 pg of CyclinA/Cdk2 (A/2) mRNA, as indicated, and subject to *in situ* hybridisation for β -III tubulin at stage 19. (B) Graphical representation of percentage of injected embryos (as indicated) displaying no difference (0), moderate increase (1), substantial increase (2), moderate decrease (-1) and complete loss (-2) of neurons on the injected site compared with the uninjected side ($n \geq 44$), *** $P \leq 0.005$.




Fig. 3. Phosphomutant Ascl1 does not affect proliferation *in vivo* and induces differentiation independently of Xic1 activity. (A) Embryos were injected in one cell of a two-cell embryo with 100 pg of either GFP or Ascl1/S-A Ascl1 mRNA, and stained for pH3, a marker of mitotic activity, at stage 19. A comparison of the number of pH3+ cells in a fixed area on the injected and uninjected sides was undertaken. Data is presented as mean normalised to wild-type Ascl1 \pm s.e.m. from two independent experiments ($n \geq 32$); $P \leq 0.05$. (B) Embryos were injected in one cell at the two-cell stage (right side) with 100 pg of either GFP or Ascl1/S-A Ascl1 mRNA, along with 45 pg of Xic1 mRNA or 20 ng Xic1 morpholino or control morpholino, as indicated, and subject to *in situ* hybridisation for β III tubulin at stage 19. (C) Graphical representation of percentage of injected embryos (as indicated) displaying no difference (0), moderate increase (1), substantial increase (2), moderate decrease (-1) and complete loss (-2) of neurons at the injected site compared with the uninjected side ($n \geq 43$), $***P \leq 0.005$.

of the transcription factor *Myt1*, a direct downstream target of *Ascl1* (Fig. 1D) (Bellefroid et al., 1996).

Overexpression of phosphomutant S-A Ascl1 in *Xenopus* embryos resulted in a sevenfold enhancement of *Myt1* expression compared with wild-type Ascl1, but only twofold enhancement of Delta

(Fig. 1D). This asymmetrical upregulation by S-A Ascl1 of *Myt1* compared with Delta may confer resistance of the phosphomutant protein to NICD-mediated inhibition. To test this, we overexpressed NICD along with wild-type or S-A Ascl1 mRNA. NICD inhibited both endogenous neurogenesis, and neurogenesis driven by wild-type Ascl1 overexpression (Fig. 4A,B), but overexpression of S-A Ascl1 led to efficient neuronal differentiation even in the presence of NICD. Thus, S-A Ascl1 showed resistance to Notch-mediated post-translational inhibition, as well as to inhibition by high levels of Cdk, providing the mechanistic basis for its enhanced ability to drive neuronal differentiation compared with wild-type protein (Figs 2 and 4).

Phosphomutant proneural proteins enhance neuronal maturation in transdifferentiation protocols

Next, we sought to examine whether phosphoregulation of Ascl1 that we observe in *Xenopus* embryos is active in mammalian systems, and especially during transdifferentiation of adult somatic cells to neurons. Numerous studies have recently demonstrated that *Ascl1* is a key factor required for direct conversion of mammalian fibroblasts into neurons *in vitro* (Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Pfisterer et al., 2011; Yang et al., 2011) and more recently *in vivo* (Torper et al., 2013). Transdifferentiation of mouse fibroblasts can be achieved by overexpression of *Brn2*, *Ascl1* and *Myt1l* (BAM) by lentiviral delivery, but addition of *NeuroD* to these 'BAM factors' (BAMN) is required for transdifferentiation of human fibroblasts (Pang et al., 2011). Although capable of firing action potentials, these neurons are morphologically immature with relatively short neurites (Yang et al., 2011). On the basis of its enhanced ability to drive neuronal differentiation *in vivo* in the presence of cues that would normally limit neurogenesis (Figs 1-4), we hypothesized that phosphomutant Ascl1 may also enhance neuronal transdifferentiation *in vitro*. To test this, and switching to human Ascl1 (ASCL1) protein for use in these human cells (supplementary material Fig. S1), we substituted S-A ASCL1 (supplementary material Fig. S1) for wild-type ASCL1 in established protocols to compare neuron generation and maturation from human fibroblasts (Fig. 5). We saw that ASCL1 and S-A ASCL1 are expressed at equal mRNA and protein levels after lentiviral transduction into HFL1 cells (supplementary material Fig. S5B,C).

S-A BAM (S-A ASCL1, *BRN2* and *MYT1L*) doubled the conversion efficiency of human fibroblasts to neurons compared with wild-type BAM (wild-type ASCL1, *BRN2* and *MYT1L*), whereas the addition of *NEUROD* to S-A BAM (S-A BAMN) did not further enhance this efficiency (Fig. 5B). We next measured the morphological complexity and functional maturity of the neurons generated using BAM and BAMN protocols, using wild-type or S-A ASCL1. After 3 weeks of neuronal conversion *in vitro*, we measured several parameters of morphological maturity, including neurite length, neurite extension, branching and axonal complexity. Neurons generated using S-A ASCL1 had substantially enhanced morphological maturity compared with those generated using wild-type ASCL1 (Fig. 5C-G). In particular, we saw a significant enhancement in the number of neuronal branch points and the number of neurons displaying tertiary branching events. This enhanced branching is further evidenced by a 50% increase in the axonal complexity index, a numerical value that reflects the overall complexity of axonal projections from a population of neurons (Marshak et al., 2007).

To investigate electrophysiological maturity, patch-clamp recordings were performed on transdifferentiated neurons 6 weeks after infection.




Fig. 4. Phosphomutant Ascl1 confers resistance to lateral inhibition. (A) *Xenopus* embryos were injected in one cell at the two-cell stage, injected side to the right, with either 100 pg of GFP or wild-type/S-A Ascl1 mRNA, and 1 ng of NICD mRNA, as indicated, and stained for β -III tubulin at stage 19. (B) Graphical representation of percentage of injected embryos displaying no difference (0), moderate increase (1), substantial increase (2), moderate decrease (-1) and complete loss (-2) of neurons at the injected site compared with the uninjected side ($n \geq 52$) *** $P \leq 0.005$.

Neurons were treated with stepwise current injections to determine their capacity to fire action potentials. Neurons generated using S-A *ASCL1* showed a significantly enhanced ability to trigger successive action potentials in response to current injections when compared to wild-type *ASCL1* (Fig. 5H). For both S-A BAM and S-A BAMN-derived neurons, we observed fast inward and outward currents in response to stepwise voltage depolarizations, corresponding to opening of voltage-gated Na^+ and K^+ channels, respectively (Fig. 5I). Larger currents were elicited in S-A BAMN-derived neurons, again signifying greater functional maturity.

Small molecule (SM) inhibitors of SMAD pathways and GSK3 β have been included along with the proneural proteins Ascl1 and Ngn2 in human fibroblast reprogramming protocols to enhance neuronal maturity (Ladewig et al., 2012). We wished to investigate whether SMs work by dephosphorylating proneural proteins to increase their activity, which would result in no synergy between S-A BAMN and SMs, or alternatively whether maturity could be further enhanced by combining SMs with phosphomutant proneural proteins, indicating parallel pathways. Consequently, we undertook fibroblast reprogramming in the presence of SMs using S-A *ASCL1* along with S-A mouse *Ngn2*, which we previously showed to have enhanced neuronal differentiation activity compared to wild-type *Ngn2* (Ali et al., 2011). Again, neurons generated with these phosphomutant proneural proteins show significantly enhanced maturity (Fig. 6A), as evidenced by neurite length and innervation area (Fig. 6B) compared with wild type. In addition, branching was fourfold greater, of higher order and the axonal complexity index was doubled (Fig. 6B).

Whole cell electrophysiological recordings were performed on neurons generated using wild-type *ASCL1*+ wild-type *Ngn2* and S-A *ASCL1*+ S-A *Ngn2* 6 weeks post-infection. Neurons generated by both wild-type and phosphomutant proneural factors had excitable membrane properties (Fig. 6C), with inward sodium and outward potassium currents (Fig. 6D). However, mean peak sodium current amplitudes in S-A *ASCL1*+ S-A *Ngn2*-induced neurons were notably larger than in wild-type-induced neurons (Fig. 6D), and resting membrane potentials in phosphomutant-derived neurons were significantly more negative compared with wild-type controls. In contrast to the weak action potentials elicited by wild-type factors, neurons induced with phosphomutant factors triggered sustained mature action potential firing (Fig. 6C). Altogether, these data demonstrate that neurons induced using S-A *ASCL1* and S-A *Ngn2* had neuronal membrane and action potential firing properties that were markedly more mature than neurons generated using a standard wild-type *ASCL1* and wild-type *Ngn2* protocol.

DISCUSSION

In this study, we demonstrate that the ability of the Ascl1 protein to drive neuronal differentiation is regulated by multisite phosphorylation on serine-proline sites. Ascl1 is phosphorylated on multiple sites on both its N- and C-terminals. Preventing phosphorylation results in upregulation of key differentiation targets such as Myt1 and neural beta-tubulin. Interestingly, the upregulation of these differentiation targets is greater than the Ascl1 target Delta, which mediates Notch-dependent non-cell autonomous progenitor maintenance, accounting for the enhanced neurogenesis seen with the phosphomutant protein.

We have previously shown that multisite phosphorylation of the proneural protein Ngn2 by Cdks inhibits both its ability to bind stably to DNA, and its ability to drive neuronal differentiation (Ali et al., 2011; Hindley et al., 2012) in a manner analogous to the phosphoregulation of Ascl1 we present here. We propose that, similar to Ngn2, differential sensitivity of downstream targets to Ascl1 phosphorylation probably results from differences in the requirement for epigenetic remodelling by Ascl1 for activation; epigenetically available targets tolerate a potentially low promoter dwell time of phosphorylated Ascl1 whereas those requiring substantial modification for activation, often genes associated with differentiation such as Myt1 and neural beta tubulin, require more stable association to bring about the epigenetic changes needed for activation (Ali et al., 2011). The similarities between the regulation of Ngn2 and Ascl1 raises the possibility that multisite S-P directed phosphorylation by Cdks may be a general mechanism to control differentiation activity of other proneural proteins in the nervous system in response to cell cycle and signalling cues.

In the case of Ngn2, we saw that it was the number of phospho-sites available that controlled the ability of the protein to drive neuronal differentiation, not their precise location (Ali et al., 2011). The same seems to be true for Ascl1. Ascl1 is phosphorylated on both N- and C-terminal sites, and preventing phosphorylation of both terminals of the molecule is required for maximal activity of the protein. Although mouse Ascl1 contains an additional N-terminal SP site not found in the human protein, both human and mouse Ascl1 S-A mutants show significantly enhanced activity driving neuronal differentiation, indicating that this SP site does not play an extra key regulatory role in Ascl1. We see that multiple sites can be phosphorylated by Cdk2 (supplementary material Figs S3 and S4), although we do not rule out the possibility that these sites can be targeted by other Cdks or indeed other proline-directed kinases.

We propose that Ascl1 multisite phosphoregulation is a mechanism to sense and respond to Cdk and Cdk inhibitor levels (Figs 2 and 3) and hence the cycling activity of progenitor cells. Phospho-status of Ascl1 also regulates sensitivity to post-translational inhibition mediated by Notch signalling (Fig. 4).




Fig. 5. Phosphomutant Ascl1 promotes neuronal maturity of transdifferentiated neurons. (A) HFL1-derived transdifferentiated neurons 21 days after transduction with wild-type or S-A *ASCL1* in BAM or BAM+*NEUROD* protocols, as indicated, DNA (blue), Tuj1 (green). (B) Sixty randomly selected 10× visual fields were counted to determine the percentage of Hoechst-positive cells that are also Tuj1 positive. (C-G) Forty-nine or more neurons were measured to determine quantitative measurements of morphological maturation. B-G are presented as mean±s.e.m. for a duplicate experiment; * $P \leq 0.05$; *** $P \leq 0.005$. (H) Representative traces of action potentials in response to step current injections 42 days post-induction (−4 to +26 pA for wild-type BAM, −200 to +500 pA for wild-type BAMN, −4 to +14 pA for S-A BAM, −4 to +14 pA for S-A BAMN). (I) Representative traces of inward sodium and outward potassium currents in response to step depolarisations from a holding potential of −80 to +40 mV in voltage clamp mode. Scale bars: 200 μm. WT, wild type.

Notch signalling has been shown to both inhibit neurogenesis and suppress maturation of neurons already born (Giniger, 2012). The precise molecular mechanism of post-translational inhibition by Notch signalling is not clear, although inhibition of Ngn2 protein can be relieved by overexpression of *Xenopus* Myt1. As S-A Ascl1 upregulates Myt1 sevenfold more effectively than wild-type Ascl1, this is likely to be the way it escapes Notch-mediated inhibition. The ability of phosphomutant Ascl1 to resist Notch-mediated as well as Cdk-mediated inhibition may be key to its ability to overcome cellular signals limiting neuronal transdifferentiation in human fibroblasts, and its use in reprogramming cocktails results in enhanced neuronal differentiation *in vitro* compared with the wild-type protein (Figs 5 and 6).

Recently, Ascl1 has been identified as an ‘on-target pioneer factor’ defined as a transcription factor that can bind its targets when either accessible or nucleosome-bound (Wapinski et al., 2013). Nucleosome-bound targets of Ascl1 in fibroblasts are characterized by a trivalent chromatin signature consisting of enriched H3K4Me1, H3K27ac and H3K9me3, and cell types such

as keratinocytes that do not show this trivalent signature at Ascl1 targets are resistant to BAM factor reprogramming. S-A *ASCL1* is modestly better than the wild-type protein at converting fibroblasts to neurons (Figs 5 and 6) but is significantly better at inducing maturation of the neurons so generated. This may result from enhanced chromatin binding of the phosphomutant protein on promoters of key targets driving maturation (Hindley et al., 2012), although it is not yet clear whether enhanced maturity results from a higher expression of the same targets as are activated by wild-type Ascl1 (Fig. 1D), or whether S-A Ascl1 can activate additional targets with less favourable chromatin configurations. As genome-wide targets of Ascl1 in fibroblasts have now been identified, this question can be assessed, along with testing the ability of S-A Ascl1 to reprogram cell types that do not have these permissive trivalent marks at target promoters. As well as acting as a pioneer factor, Ascl1 recruits Brn2 to responsive promoters (Wapinski et al., 2013); enhanced co-factor recruitment is another possible mechanism to potentiate S-A Ascl1 ability to drive neuronal differentiation and transdifferentiation.




Fig. 6. Phosphomutant proneural proteins promote neuronal maturity of transdifferentiated neuronal cells in combination with SMs. (A) Immunofluorescence illustrating representative morphologies of transdifferentiated neurons stained for β III-tub (red), MAP2 (green) expression and DNA (DAPI, blue) of HFL1 cultures under SM conditions at 21 days after transduction with either wild-type *ASCL1* and wild-type *Ngn2* or S-A *ASCL1* and S-A *Ngn2*. (B) Quantitative measurements of morphological maturation comparing transdifferentiated neurons derived after either wild-type *ASCL1* and wild-type *Ngn2* or S-A *ASCL1* and S-A *Ngn2* transductions under SM conditions. (C, D) Whole-cell electrophysiological properties of wild-type *ASCL1* and wild-type *Ngn2* or S-A *ASCL1* and S-A *Ngn2* transdifferentiated neurons, as labeled at 42 days after transduction. (C) Action potential firing in response to 10 pA steps of current injection from -20 pA to $+50$ pA. (D) Inward sodium currents and outward potassium currents triggered in response to voltage steps from -80 mV to $+50$ mV ($+30$, 40 , 50 mV shown) from a holding potential of -70 mV. Scale bars: $200 \mu\text{m}$.

Our developmental findings pointed to a potentially enhanced ability of phosphomutant *Ascl1* to enhance neuronal maturation after reprogramming of human fibroblasts, and this was indeed the case (Figs 5 and 6). A more in-depth study of mechanisms of developmental post-translational regulation of factors used in reprogramming protocols offers a potentially powerful platform to identify signalling pathways and regulatory mechanisms that facilitate and suppress differentiation and transdifferentiation *in vivo* and *in vitro*.

MATERIALS AND METHODS

Xenopus laevis extracts and embryos

Acquisition of *Xenopus laevis* eggs and embryos, preparation and injection of synthetic mRNA, staging of embryos, *in situ* hybridisation, pH3 analysis egg extract preparation and preparation and western blotting of embryo extracts were performed as described previously (Vernon et al., 2003;

Vosper et al., 2007, 2009; Philpott and Friend, 1994; Richard-Parpaillon et al., 2004).

Xenopus embryos scoring scheme

Xenopus embryos scoring scheme was as described previously (Ali et al., 2011). Embryos were assigned scores from -2 to $+2$ based on the neuronal staining by *in situ* hybridisation on the injected side (identified by the co-injected lineage-tracer beta-gal, on the right in all figures) compared to the uninjected side: 0 , no difference; -1 , a small decrease in staining; -2 a large decrease or no staining; $+1$, a small increase in staining; $+2$, a large increase in staining, often with staining outside of the neural plate.

In vitro phosphorylation using recombinant Cdk

Ascl1^{35S}-labelled IVT protein was incubated with 250 ng of the indicated recombinant cyclin/Cdk complex (Cell Signaling Technology) with $87.5 \mu\text{M}$ ATP. The reaction was incubated at 30°C for 1 h, then denatured, resolved by SDS-PAGE and analysed by autoradiography.

Cell culture and lentiviral preparations

HFL1 (ATCC-CCL-153) cells were maintained and expanded in DMEM + GlutaMAX (Gibco) supplemented with 10% FBS (HyClone) and 100 units/ml penicillin, 100 µg/ml streptomycin (Sigma). P19 cells were cultured in α -MEM with 7.5% newborn calf serum and 2.5% fetal bovine serum, 1% Glutamax, and 100 units/ml penicillin, 100 µg/ml streptomycin. Human open reading frame for Ascl1, S-A Ascl1, Brn2, Myt1l, NeuroD, Ngn2 and S-A Ngn2 were cloned into a doxycycline-regulated lentiviral vectors (pLVX-TRE3G). Viruses were generated in HEK293T cells and titres were determined using the Lenti-X Tet-On 3G Inducible Expression System (Clontech) according to the manufacturer's instructions.

Quantitative PCR

For qPCR analysis, embryos were injected at the one-cell stage with mRNA as indicated. RNA extraction and qPCR analysis were performed as described previously (Ali et al., 2011). The sequences of the primers used were: Delta forward: GCCCAGAGATGATGCTTTC, Delta reverse: GCCTTGCCAA-CCCACTCTACATT, Myt1 forward: AAGTTTGTATGCTCAGGTTTTT-GGC, Myt1 reverse: AGAGGAGGAGGAAGAGGAAGTGCT, β -III tubulin forward: ACACGGCATTGATCCTACAG, β -III tubulin reverse: AGCTCC-TTCGGTGAATGAC.

Generation of transdifferentiated neurons and immunostaining

Neuronal conversion was performed as described previously (Pang et al., 2011). Cells were co-transduced with a Tet-On transactivator (LVX-Tet3G) and LVX-TRE3G-encoding genes of interest at ratio of 1:1 and multiplicity of infection of 5. Cells were left to proliferate for 5 days before induction with 1 µg/ml doxycyclin. During neuronal conversion, cells were maintained in neuronal media (NDiff 227) (StemCells). Where indicated, small molecule inhibitors of the SMAD signalling pathway [SB431542 (Sigma), Noggin (R&D Systems) and LDN-193189 (Miltenyi Biotech) together with GSK-3 β inhibitor CHIR99021 (Miltenyi Biotech)] were added for 2 weeks in neuronal media at the concentrations previously described (Ladewig et al., 2012). Neurotrophic factors BDNF, GDNF, NT3 (R&D Systems) and dcAMP (Sigma) were supplemented in the neuronal media at the concentrations previously described (Ladewig et al., 2012) to promote prolonged neuronal survival. Six weeks post-transduction, cells were stained for β -tubulin; 1:1000 (Covance) and chicken anti-MAP2 1:10,000 (Abcam) as previously described (Pfisterer et al., 2011). Conversion efficiency was calculated as the percentage of β -III tubulin-positive cells across 60 randomly selected 20 \times visual fields. Neurite length, innervation area and branching were traced using the ImageJ software for 60 randomly selected 10 \times images. Axonal complexity was calculated using the axonal complexity index (ACI), modified from Marshak et al. (Marshak et al., 2007).

Electrophysiology

Whole-cell recordings were performed on cells with neuronal morphology at room temperature in artificial spinal fluid: 125 mM NaCl, 25 mM NaHCO₃, 1.25 mM NaH₂PO₄, 3 mM KCl, 2 mM CaCl₂, 25 mM glucose and 3 mM pyruvic acid, bubbled with 95% O₂ and 5% CO₂. Borosilicate glass electrodes (resistance 6-10 M Ω) were filled with an intracellular solution containing 135 mM potassium gluconate, 7 mM NaCl, 10 mM HEPES, 2 mM Na₂ATP, 0.3 mM Na₂GTP and 2 mM MgCl₂. To detect sodium and potassium currents, step depolarizations were made from a holding potential of -80 to +40 mV in voltage clamp mode. Sodium currents were blocked with 1 µM tetrodotoxin (Tocris). To detect action potential firing, stepwise current injections were performed in current clamp mode. Recordings were made with a Multiclamp 700 A amplifier (Molecular Devices) and a Digidata 1440 (Molecular Devices). Signals were filtered at 6 kHz, sampled at 20 kHz with 16-bit resolution. Data acquisition and analysis was performed using pCLAMP (Molecular Devices).

Statistical analysis

Statistical analysis for qPCR and neuronal profiling were performed using a one-tailed Student's *t*-test (**P*≤0.05; ****P*≤0.005); standard error of the mean (s.e.m.) calculated from at least two independent experiments. The Fisher exact statistical test was performed on the *Xenopus* embryos scoring scheme (***P*≤0.01; ****P*≤0.005).

Acknowledgements

We thank Malin Parmar, Francois Guillemot, Masashi Narita, John Davies and Alison Jones for reagents and helpful discussions and to Laura Hardwick for help with statistical analysis.

Competing interests

The authors declare no competing financial interests.

Author contributions

A.P. conceived the study; F.A., K.C. and A.P. undertook experimental design and experiments; P.K. and R.L. undertook electrophysiology; R.B. and S.M. contributed to experimental design; and all authors contributed to essential discussions and manuscript preparation.

Funding

Work was supported by the Medical Research Council [grant G0700758 to A.P. and Doctoral Training Award to K.C.], and the Rosetrees Trust. F.A. is supported by the National Institute for Health Research (NIHR) under its Invention for Innovation (i4i) Programme [grant II-AR-1109-11037 to R.A.B. and S.M.], with some support from NIHR Biomedical Research Centre award to Addenbrookes Hospital, University of Cambridge. Deposited in PMC for release after 6 months.

Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.106377/-/DC1>

References

- Ali, F., Hindley, C., McDowell, G., Deibler, R., Jones, A., Kirschner, M., Guillemot, F. and Philpott, A. (2011). Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis. *Development* **138**, 4267-4277.
- Bellefroid, E. J., Bourguignon, C., Hollemann, T., Ma, Q., Anderson, D. J., Kintner, C. and Pieler, T. (1996). X-Myt1, a *Xenopus* C2HC-type zinc finger protein with a regulatory function in neuronal differentiation. *Cell* **87**, 1191-1202.
- Bertrand, N., Castro, D. S. and Guillemot, F. (2002). Proneural genes and the specification of neural cell types. *Nat. Rev. Neurosci.* **3**, 517-530.
- Caiazzo, M., Dell'Anno, M. T., Dvoretzskova, E., Lazarevic, D., Taverna, S., Leo, D., Sotnikova, T. D., Menegon, A., Roncaglia, P., Colciago, G. et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* **476**, 224-227.
- Casarosa, S., Fode, C. and Guillemot, F. (1999). Mash1 regulates neurogenesis in the ventral telencephalon. *Development* **126**, 525-534.
- Castro, D. S. and Guillemot, F. (2011). Old and new functions of proneural factors revealed by the genome-wide characterization of their transcriptional targets. *Cell Cycle* **10**, 4026-4031.
- Chitnis, A., Henrique, D., Lewis, J., Ish-Horowicz, D. and Kintner, C. (1995). Primary neurogenesis in *Xenopus* embryos regulated by a homologue of the *Drosophila* neurogenic gene Delta. *Nature* **375**, 761-766.
- Errico, A., Deshmukh, K., Tanaka, Y., Pozniakovsky, A. and Hunt, T. (2010). Identification of substrates for cyclin dependent kinases. *Adv. Enzyme Regul.* **50**, 375-399.
- Farah, M. H., Olson, J. M., Sucic, H. B., Hume, R. I., Tapscott, S. J. and Turner, D. L. (2000). Generation of neurons by transient expression of neural bHLH proteins in mammalian cells. *Development* **127**, 693-702.
- Gaber, Z. B. and Novitsch, B. G. (2011). All the embryo's a stage, and Olig2 in its time plays many parts. *Neuron* **69**, 833-835.
- Giniger, E. (2012). Notch signaling and neural connectivity. *Curr. Opin. Genet. Dev.* **22**, 339-346.
- Hindley, C. and Philpott, A. (2012). Co-ordination of cell cycle and differentiation in the developing nervous system. *Biochem. J.* **444**, 375-382.
- Hindley, C., Ali, F., McDowell, G., Cheng, K., Jones, A., Guillemot, F. and Philpott, A. (2012). Post-translational modification of Ngn2 differentially affects transcription of distinct targets to regulate the balance between progenitor maintenance and differentiation. *Development* **139**, 1718-1723.
- Ladewig, J., Mertens, J., Kesavan, J., Doerr, J., Poppe, D., Glaue, F., Herms, S., Wernet, P., Kögler, G., Müller, F. J. et al. (2012). Small molecules enable highly efficient neuronal conversion of human fibroblasts. *Nat. Methods* **9**, 575-578.
- Lange, C. and Calegari, F. (2010). Cdks and cyclins link G(1) length and differentiation of embryonic, neural and hematopoietic stem cells. *Cell Cycle* **9**, 1893-1900.
- Ma, Y.-C., Song, M.-R., Park, J. P., Henry Ho, H.-Y., Hu, L., Kurtev, M. V., Zieg, J., Ma, Q., Pfaff, S. L. and Greenberg, M. E. (2008). Regulation of motor neuron specification by phosphorylation of neurogenin 2. *Neuron* **58**, 65-77.
- Marshak, S., Nikolakopoulou, A. M., Dirks, R., Martens, G. J. and Cohen-Cory, S. (2007). Cell-autonomous TrkB signaling in presynaptic retinal ganglion cells

- mediates axon arbor growth and synapse maturation during the establishment of retinotectal synaptic connectivity. *J. Neurosci.* **27**, 2444-2456.
- Pang, Z. P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D. R., Yang, T. Q., Citri, A., Sebastiano, V., Marro, S., Südhof, T. C. et al.** (2011). Induction of human neuronal cells by defined transcription factors. *Nature* **476**, 220-223.
- Pfisterer, U., Kirkeby, A., Torper, O., Wood, J., Nelander, J., Dufour, A., Bjorklund, A., Lindvall, O., Jakobsson, J. and Parmar, M.** (2011). Direct conversion of human fibroblasts to dopaminergic neurons. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 10343-10348.
- Philpott, A. and Friend, S. H.** (1994). E2F and its developmental regulation in *Xenopus laevis*. *Mol. Cell. Biol.* **14**, 5000-5009.
- Philpott, A. and Yew, P. R.** (2008). The *Xenopus* cell cycle: an overview. *Mol. Biotechnol.* **39**, 9-19.
- Richard-Parpaillon, L., Cosgrove, R. A., Devine, C., Vernon, A. E. and Philpott, A.** (2004). G1/S phase cyclin-dependent kinase overexpression perturbs early development and delays tissue-specific differentiation in *Xenopus*. *Development* **131**, 2577-2586.
- Talikka, M., Perez, S. E. and Zimmerman, K.** (2002). Distinct patterns of downstream target activation are specified by the helix-loop-helix domain of proneural basic helix-loop-helix transcription factors. *Dev. Biol.* **247**, 137-148.
- Torper, O., Pfisterer, U., Wolf, D. A., Pereira, M., Lau, S., Jakobsson, J., Bjorklund, A., Grealish, S. and Parmar, M.** (2013). Generation of induced neurons via direct conversion in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 7038-7043.
- Vernon, A. E., Devine, C. and Philpott, A.** (2003). The cdk inhibitor p27^{Xic1} is required for differentiation of primary neurones in *Xenopus*. *Development* **130**, 85-92.
- Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Südhof, T. C. and Wernig, M.** (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* **463**, 1035-1041.
- Vosper, J. M., Fiore-Herich, C. S., Horan, I., Wilson, K., Wise, H. and Philpott, A.** (2007). Regulation of neurogenin stability by ubiquitin-mediated proteolysis. *Biochem. J.* **407**, 277-284.
- Vosper, J. M., McDowell, G. S., Hindley, C. J., Fiore-Herich, C. S., Kucerova, R., Horan, I. and Philpott, A.** (2009). Ubiquitylation on canonical and noncanonical sites targets the transcription factor neurogenin for ubiquitin-mediated proteolysis. *J. Biol. Chem.* **284**, 15458-15468.
- Wapinski, O. L., Vierbuchen, T., Qu, K., Lee, Q. Y., Chanda, S., Fuentes, D. R., Giresi, P. G., Ng, Y. H., Marro, S., Neff, N. F. et al.** (2013). Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. *Cell* **155**, 621-635.
- Yang, N., Ng, Y. H., Pang, Z. P., Südhof, T. C. and Wernig, M.** (2011). Induced neuronal cells: how to make and define a neuron. *Cell Stem Cell* **9**, 517-525.